Show simple item record

dc.contributor.authorFuchs, Julian E.es_ES
dc.contributor.authorMuñoz, Inés G.es_ES
dc.contributor.authorTimson, David J.es_ES
dc.contributor.authorPey, Ángel L.es_ES
dc.date.accessioned2016-10-18T07:05:32Z
dc.date.available2016-10-18T07:05:32Z
dc.date.issued2016
dc.identifier.citationFuchs, J.E.; Muñoz, I.G.; Timson, D.J.; Pey, A.L. Experimental and computational evidence on conformational fluctuations as a source of catalytic defects in genetic diseases. RSC Advances, 6: 58604-58612 (2016). [http://hdl.handle.net/10481/42968]es_ES
dc.identifier.issn2046-2069
dc.identifier.urihttp://hdl.handle.net/10481/42968
dc.description.abstractTheoretical and experimental evidence has shown that protein function, regulation and degradation are intrinsically linked to the dynamic and fluctuating nature of protein ensembles. However, the effect of missense mutations on catalytic performance are often interpreted from conformational analyses derived from X-ray crystallography, molecular dynamics and modeling, while effects on conformational fluctuations at the active site as the source of catalytic defects are rarely investigated. Here, we explore the role of conformational fluctuations in the catalytic efficiency of WT and three missense mutations in the UDP-galactose 4′-epimerase (GALE) protein causing type III galactosemia. Using comprehensive molecular dynamics simulations and small angle X-ray scattering we correlate low NAD+ binding affinity in some mutants with an increased population of non-competent conformations for NAD+ binding. Proteolysis studies combined with thermodynamic calculations reveal that mutations affecting GALE catalytic performance favor larger conformational fluctuations at the N-terminal domain and NAD+ binding site, shifting the equilibrium towards non-binding competent states in the native ensemble. Therefore, we provide a novel ensemble-based thermodynamic mechanism to explain catalytic defects caused by missense mutations that links large and transient conformational fluctuations and loss of catalytic efficiency and substrate/coenzyme affinity. In the context of this mechanism, we propose that allosteric ligands aimed at modulating these transient conformational fluctuations might correct catalytic defects in inherited metabolic diseases, representing a different approach to current small ligand therapies which target the low stability, but not catalytic defects, of mutations.es_ES
dc.description.sponsorshipThis work was supported by grants from MINECO (BIO2015-66426-R, CSD2009-00088) and Junta de Andaluc´ıa (P11-CTS-07187). A. L. P. was supported by a Ram´on y Cajal research contract from MINECO/University of Granada (RYC-2009-04147).es_ES
dc.language.isoenges_ES
dc.publisherRoyal Society of Chemistryes_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es_ES
dc.subjectGenetic diseaseses_ES
dc.subjectProteines_ES
dc.subjectConformational fluctuationses_ES
dc.subjectCatalysis es_ES
dc.subjectInherited metabolic diseaseses_ES
dc.titleExperimental and computational evidence on conformational fluctuations as a source of catalytic defects in genetic diseaseses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1039/C6RA05499D


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License